Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28145187 | 0.80 | RECQL (0.38) | RECQL | |
| SCHEMBL2775882 | 0.79 | RECQL (0.33) | RECQL | |
| SCHEMBL8861555 | 0.78 | RECQL (0.32) | RECQL | |
| SCHEMBL1742070 | 0.78 | RECQL (0.38) | RECQL | |
| SCHEMBL2305604 | 0.78 | KDM6B (0.31) | RECQL | |
| SCHEMBL19327562 | 0.78 | TSHR (0.32) | — | |
| SCHEMBL1580299 | 0.74 | TSHR (0.35) | RECQL | |
| SCHEMBL669686 | 0.74 | SMN1; SMN2 (0.31) | — | |
| Sulfuric Acid SCHEMBL10888225 | 0.71 | SLC22A6 (0.35) | RECQL | |
| SCHEMBL22717361 | 0.70 | DGKA (0.44) | RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119816334-A | Sealant for tissue closure | 爱惜康股份有限公司 | 2025-04-11 | — | — | CN | claimed |
| US-20230126856-A1 | REAGENTS FOR RAPID CHIRAL LABELING AND ANALYSIS OF AMINE CONTAINING ENANTIOMERS | WATERS TECHNOLOGIES CORPORATION (US) | 2023-04-27 | — | — | US | claimed |
| CN-107106719-B | Tissue-adhesive porous hemostatic product | 加特技术公司 | 2021-06-01 | — | — | CN | claimed |
| US-10925996-B2 | Cross-linked polymers and implants derived from electrophilically activated polyoxazoline | GATT TECHNOLOGIES BV (NL) | 2021-02-23 | — | — | US | claimed |
| US-10751441-B2 | Tissue-adhesive porous haemostatic product | GATT TECHNOLOGIES B.V. (NL) | 2020-08-25 | — | — | US | claimed |
| EP-3446721-B1 | CROSS-LINKED POLYMERS AND IMPLANTS DERIVED FROM ELECTROPHILICALLY ACTIVATED POLYOXAZOLINE | GATT TECH B V (NL) | 2020-03-11 | — | — | EP | claimed |
| US-20190231923-A1 | CROSS-LINKED POLYMERS AND IMPLANTS DERIVED FROM ELECTROPHILICALLY ACTIVATED POLYOXAZOLINE | GATT TECHNOLOGIES B.V. (NL) | 2019-08-01 | — | — | US | claimed |
| US-10314936-B2 | Cross-linked polymers and implants derived from electrophilically activated polyoxazoline | GATT TECHNOLOGIES BV (NL) | 2019-06-11 | — | — | US | claimed |
| US-20190125922-A1 | TISSUE-ADHESIVE POROUS HAEMOSTATIC PRODUCT | GATT TECHNOLOGIES B.V. (NL) | 2019-05-02 | — | — | US | claimed |
| EP-2661283-B1 | CROSS-LINKED POLYMERS AND IMPLANTS DERIVED FROM ELECTROPHILICALLY ACTIVATED POLYOXAZOLINE | GATT TECH B V (NL) | 2019-03-27 | — | — | EP | claimed |
| WO-2016056901-A1 | TISSUE-ADHESIVE POROUS HAEMOSTATIC PRODUCT | GATT TECHNOLOGIES B.V. (NL) | 2016-04-14 | — | — | WO | claimed |
| EP-2825582-B1 | CROSS-LINKED POLYMERS AND MEDICAL PRODUCTS DERIVED FROM NUCLEOPHILICALLY ACTIVATED POLYOXAZOLINE | BENDER ANALYTICAL HOLDING BV (NL) | 2016-01-13 | — | — | EP | claimed |
| US-20150045507-A1 | CROSS-LINKED POLYMERS AND MEDICAL PRODUCTS DERIVED FROM NUCLEOPHILICALLY ACTIVATED POLYOXAZOLINE | BENDER ANALYTICAL HOLDING B.V. (NL) | 2015-02-12 | — | — | US | claimed |
| EP-2825582-A1 | CROSS-LINKED POLYMERS AND MEDICAL PRODUCTS DERIVED FROM NUCLEOPHILICALLY ACTIVATED POLYOXAZOLINE | Bender Analytical Holding B.V. (NL) | 2015-01-21 | — | — | EP | claimed |
| EP-2755691-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | Prolynx LLC (US) | 2014-07-23 | — | — | EP | claimed |
| US-20130345334-A1 | CROSS-LINKED POLYMERS AND IMPLANTS DERIVED FROM ELECTROPHILICALLY ACTIVATED POLYOXAZOLINE | BENDER ANALYTICAL HOLDING B.V. (NL) | 2013-12-26 | — | — | US | claimed |
| EP-2661283-A2 | CROSS-LINKED POLYMERS AND IMPLANTS DERIVED FROM ELECTROPHILICALLY ACTIVATED POLYOXAZOLINE | Bender Analytical Holding B.V. (NL) | 2013-11-13 | — | — | EP | claimed |
| WO-2013137736-A1 | CROSS-LINKED POLYMERS AND MEDICAL PRODUCTS DERIVED FROM NUCLEOPHILICALLY ACTIVATED POLYOXAZOLINE | BENDER ANALYTICAL HOLDING B.V. (NL) | 2013-09-19 | — | — | WO | claimed |
| WO-2013036847-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | PROLYNX LLC (US) | 2013-03-14 | — | — | WO | claimed |
| WO-2012057628-A2 | CROSS-LINKED POLYMERS AND IMPLANTS DERIVED FROM ELECTROPHILICALLY ACTIVATED POLYOXAZOLINE | BENDER ANALYTICAL HOLDING B.V. (NL) | 2012-05-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126856-A1 | REAGENTS FOR RAPID CHIRAL LABELING AND ANALYSIS OF AMINE CONTAINING ENANTIOMERS | AMD1, AADAT, SRM | RECQL 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.